Cytek Biosciences, Inc. Gross Profit 2020–2025
Cytek Biosciences, Inc. reported $104.46M of gross profit for fiscal 2025. That was 6.0% lower than fiscal 2024. Compared with fiscal 2020, the change was +102.0%.
| Fiscal year | Gross Profit | Gross margin | Change (YoY) |
|---|---|---|---|
| FY 2025 | $104.46M | 51.8% | -6.0% |
| FY 2024 | $111.11M | 55.4% | +1.5% |
| FY 2023 | $109.43M | 56.6% | +8.4% |
| FY 2022 | $100.97M | 61.6% | +27.6% |
| FY 2021 | $79.14M | 3628.8% | +53.1% |
| FY 2020 | $51.71M | 7283.1% | — |
Source: Cytek Biosciences, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open CTKB 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Cytek Biosciences, Inc. reported $104.46M of gross profit for fiscal 2025. That was 6.0% lower than fiscal 2024. Compared with fiscal 2020, the change was +102.0%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Cytek Biosciences, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCytek Biosciences, Inc. — frequently asked questions
What is Cytek Biosciences, Inc.'s gross profit?
Cytek Biosciences, Inc. (CTKB) reported gross profit of $104.46M for fiscal year 2025, per its SEC filings.
How has Cytek Biosciences, Inc.'s gross profit changed over time?
Between fiscal 2020 and 2025, CTKB's gross profit grew at roughly 15.1% per year (compound annual rate), from $51.71M to $104.46M.
Where does this data come from?
Figures are computed from Cytek Biosciences, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.